VEGF‐C and Mortality in Patients With Suspected or Known Coronary Artery Disease

Wada, Hiromichi; Suzuki, Masahiro; Matsuda, Morihiro; Ajiro, Yoichi; Shinozaki, Tsuyoshi; Sakagami, Satoru; Yonezawa, Kazuya; Shimizu, Masatoshi; Funada, Junichi; Takenaka, Takashi; Morita, Yukiko; Nakamura, Toshihiro; Fujimoto, Kazuteru; Matsubara, Hiromi; Kato, Toru; Unoki, Takashi; Takagi, Daisuke; Ura, Shogo; Wada, Kyohma; Iguchi, Moritake; Masunaga, Nobutoyo; Ishii, Mitsuru; Yamakage, Hajime; Shimatsu, Akira; Kotani, Kazuhiko; Satoh‐Asahara, Noriko; Abe, Mitsuru; Akao, Masaharu; Hasegawa, Koji

doi:10.1161/jaha.118.010355

Cited by 39 publications

(31 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Conversely, in the cohort of men who chewed betel quid, those carrying the VEGF-C polymorphism who also smoked were 2.7-18.2-fold to have oral cancer compared to those who carried the wild type but did not smoke. Interestingly, Japanese research has found that having a low VEGF-C level is significantly and inversely associated with all-cause mortality among patients with suspected or known coronary artery disease, which contrasts with the fact that high VEGF-C levels are apparently associated with poor prognosis in patients with malignancies [19].…”

Section: Discussionmentioning

confidence: 96%

“…VEGF-C SNPs have prognostic value in various diseases [17][18][19]. A Taiwanese study has reported that the VEGF-C rs1485766 polymorphism appears to contribute to the risk of urothelial cell carcinoma (UCC) [17] .…”

Section: Discussionmentioning

confidence: 99%

“…Comparisons of SNP distribution frequencies among patient populations (e.g., patients and controls) are commonly applied to predict disease risk and prognosis, including RA [15,16]. For instance, polymorphisms of the vascular endothelial growth factor C (VEGF-C) gene can predict the risk and prognosis of various diseases, including urothelial cell carcinoma, oral cancer, and coronary artery disease [17][18][19].…”

Section: Ivyspringmentioning

confidence: 99%

“…VEGFs are pivotal regulators of angiogenesis and include 5 members in mammals: VEGF (or VEGF-A), placental growth factor, VEGF-B, VEGF-C and VEGF-D [19]. The VEGF-A signaling cascade via VEGF receptor-2 is considered to be the main angiogenic pathway [20,21].…”

Section: Ivyspringmentioning

confidence: 99%

See 3 more Smart Citations

VEGF-C Gene Polymorphisms Increase Susceptibility to Rheumatoid Arthritis

Dai

Kuo

et al. 2019

Int. J. Med. Sci.

View full text Add to dashboard Cite

Vascular endothelial growth factor C (VEGF-C) promotes angiogenesis, a prominent feature in rheumatoid synovitis, contributing to the perpetuation of the global burden of rheumatoid arthritis (RA). VEGF-C gene polymorphisms predict the risk of developing various human diseases, such as urothelial cell carcinoma, oral cancer and coronary artery disease. We sought to determine whether single nucleotide polymorphisms (SNPs) of the VEGF-C gene can predict the risk of RA. Our study recruited 210 patients with RA and 373 healthy controls between 2007 and 2015, and performed comparative genotyping for SNPs rs7664413, rs11947611, rs1485766, rs2046463 and rs3775194. In analyses adjusted for potential covariates, we found that compared with subjects with the A/A genotype of SNP rs11947611, those with the A/G genotype were 40% more likely to develop RA (adjusted odds ratio [AOR] 0.61; 95% confidence interval [CI] 0.40 to 0.92; p = 0.02). In addition, subjects lacking the A/A genotype (A/G, G/G) of SNP rs2046463 were more than twice as likely as those with the A/A genotype to require methotrexate (AOR 2.23, 95% CI 1.25 to 3.98; p = 0.01), while those who lacked the G/G genotype (G/C, C/C) in the SNP rs3775194 had a significantly lower risk of requiring prednisolone as compared with those with the G/G genotype (AOR 0.39, 95% CI 0.19 to 0.79; p = 0.01). Our findings suggest that VEGF-C gene polymorphisms might serve as a diagnostic marker and therapeutic target for RA therapy. Pharmacotherapies that modulate the activity of the VEGF-C gene may be promising for RA treatment.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Section: Ivyspringmentioning

confidence: 99%

Section: Ivyspringmentioning

confidence: 99%

See 2 more Smart Citations

VEGF-C Gene Polymorphisms Increase Susceptibility to Rheumatoid Arthritis

Dai

Kuo

et al. 2019

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

“…Otherwise it is so hard to explain that results of the ANOX Study. Indeed, in VEGF-C levels were significantly and inversely associated with all-cause death and cardiovascular death, but not with major adverse cardiovascular events (MACE) and cardiac remodeling [29]. Taking into consideration of origin of VEGF-C, MACEs have to be close related to concentration of the biomarker.…”

Section: Vegf-a Levels As Predictor Of Clinical Outcomes After Myocarmentioning

confidence: 99%

Circulating vascular endothelial growth factor in ST-segment elevation myocardial infarction: from bench to bedside

Berezin¹,

Berezin²

2019

bmgt

View full text Add to dashboard Cite

Soluble vascular endothelial growth factor receptor 2 and prognosis in patients with chronic heart failure

et al. 2021

Self Cite

View full text Add to dashboard Cite

Aims Endothelial cell vascular endothelial growth factor receptor 2 (VEGFR-2) plays a pivotal role in angiogenesis, which induces physiological cardiomyocyte hypertrophy via paracrine signalling between endothelial cells and cardiomyocytes. We investigated whether a decrease in circulating soluble VEGFR-2 (sVEGFR-2) levels is associated with poor prognosis in patients with chronic heart failure (HF). Methods and resultsWe performed a multicentre prospective cohort study of 1024 consecutive patients with HF, who were admitted to hospitals due to acute decompensated HF and were stabilized after initial management. Serum levels of sVEGFR-2 were measured at discharge. Patients were followed up over 2 years. The outcomes were cardiovascular death, all-cause death, major adverse cardiovascular events (MACE) defined as a composite of cardiovascular death and HF hospitalization, and HF hospitalization. The mean age of the patients was 75.5 (standard deviation, 12.6) years, and 57% were male. Patients with lower sVEGFR-2 levels were older and more likely to be female, and had greater proportions of atrial fibrillation and anaemia, and lower proportions of diabetes, dyslipidaemia, and HF with reduced ejection fraction (<40%). During the follow-up, 113 cardiovascular deaths, 211 all-cause deaths, 350 MACE, and 309 HF hospitalizations occurred. After adjustment for potential clinical confounders and established biomarkers [N-terminal B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin I, and high-sensitivity C-reactive protein], a low sVEGFR-2 level below the 25th percentile was significantly associated with cardiovascular death [hazard ratio (HR), 1.79; 95% confidence interval (CI), 1.16-2.74] and all-cause death (HR, 1.43; 95% CI, 1.04-1.94), but not with MACE (HR, 1.11; 95% CI, 0.86-1.43) or HF hospitalization (HR, 1.03; 95% CI, 0.78-1.35). The stratified analyses revealed that a low sVEGFR-2 level below the 25th percentile was significantly associated with cardiovascular death (HR, 1.76; 95% CI, 1.07-2.85) and all-cause death (HR, 1.49; 95% CI, 1.03-2.15) in the high-NT-proBNP group (above the median), but not in the low-NT-proBNP group. Notably, the patients with high-NT-proBNP and low-sVEGFR-2 (below the 25th percentile) had a 2.96-fold higher risk (95% CI, 1.56-5.85) for cardiovascular death and a 2.40-fold higher risk (95% CI, 1.52-3.83) for all-cause death compared with those with low-NT-proBNP and high-sVEGFR-2.

show abstract

VEGF‐C and Mortality in Patients With Suspected or Known Coronary Artery Disease

Cited by 39 publications

References 26 publications

VEGF-C Gene Polymorphisms Increase Susceptibility to Rheumatoid Arthritis

VEGF-C Gene Polymorphisms Increase Susceptibility to Rheumatoid Arthritis

Circulating vascular endothelial growth factor in ST-segment elevation myocardial infarction: from bench to bedside

Soluble vascular endothelial growth factor receptor 2 and prognosis in patients with chronic heart failure

Contact Info

Product

Resources

About